Clinical Trial Update: Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab [NA]

View source ↗

Summary

This is a completed clinical trial evaluating Polyvalent Vaccine-KLH Conjugate and Opt-821 in combination with Bevacizumab for fallopian tube cancer, ovarian ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• OPT-821
• Polyvalent Vaccine-KLH Conjugate (polyvalent vaccine-KLH conjugate)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Fallopian Tubes Cancer, Ovarian Cancer | NA | Status: COMPLETED | Results posted: 2018-05-14